Tag: Top Stocks

Categories
Technology Stocks

Dell Reports Q2 Results, but faces Supply Chain Challenges

Dell Technologies is a pre-eminent vendor of IT infrastructure products and services. Although Dell Technologies has substantial exposure to commoditized markets and carries considerable financial leverage, it expects a hybrid cloud IT to offer a growth opportunity amid Dell trimming its debt load via cash injections coming from divestitures and spinning off VMware. 

Dell Technologies’ business centers on PCs and peripherals, servers, storage, networking equipment, as well as software, services, and financial services. Its brands include Dell, Dell EMC, VMware, Secure works, and Virtustream. The company returned to the public market in late 2018 through a reverse merger of the VMware tracking stock, DVMT. The company’s largest revenue streams of commercial PCs and servers are in tough pricing environments that can rely on services and support to generate profit.

While Dell is a benefactor of heightened demand for computers and peripherals due to the pandemic, it remains hesitant about the long-term growth and competitive pricing environment of the computing market. On the other side of the business, it is expected that Dell’s hybrid-cloud portfolio can ramp up business as organizations update their infrastructure to modern solutions.

Financial Strengths

Dell is maintaining $80 fair value estimate after its second-quarter results surpassed the expectations for year-over-year revenue growth and earnings. Dell’s last traded price was 101.55 USD, whereas its fair value estimate is 80 USD, which makes it an overvalued stock. As with peers in the computer market, Dell’s rampant growth is being restrained by supply chain challenges that are expected to persist in the near term. Shares slightly dropped after Dell reported results Since returning to the public markets, the company has placed a priority on paying down its debt balance with the goal to become investment-grade. As of the end of fiscal 2021, Dell Technologies had about $48.5 billion in total debt. The Dell sale of Boomi will bring in another $4 billion, and it is expected Dell to use both transactions to pay down debt.

Bulls Say

  • As a supplier with an end-to-end IT infrastructure portfolio, Dell Technologies has significant up selling and cross-selling opportunities.
  • Through its cloud-based products, higher-margin nascent technologies, traditional hardware prowess, and VMware, the company is well-positioned to be a leader in hybrid cloud environments.
  • Dell Technologies’ healthy cash flow is focused on paying down debt and creating a more balanced long-term capital structure that can support future investments.

Company Profile

Dell Technologies, born from Dell’s 2016 acquisition of EMC, is a leading provider of servers and storage products through its ISG segment; PCs, monitors, and peripherals via its CSG division; and virtualization software through VMware. Its brands include Dell, Dell EMC, VMware (expected to be spun off toward the end of 2021), Boomi (expected to be sold by the end of 2021), Secure works, and Virtustream. The company focuses on supplementing its traditional mainstream servers and PCs with hardware and software products for hybrid-cloud environments. The Texas-based company employs around 158,000 people and sells globally.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Philosophy Technical Picks Technology Stocks

Super Retail’s strong balance sheet with plenty of room to invest

Investment Thesis

  • Trading at a discount to our valuation, with attractive trading multiples and dividend yield.
  • SUL’s four core segments have strong tailwinds/fundamentals. For example, vehicle aftermarket sales continue to be strong (with an increase in secondhand vehicles sold (Supercheap); travellers seeking social distancing and thus moving away from public transportation (Supercheap); with Covid lockdown measures in force, more people would spend their holidays domestically (BCF; macpac), utilising their vehicles (Supercheap); increasing awareness of fit and healthy living (Supercheap); (rebel).
  • A strong capital position.
  • Strong brands in BCF, Macppac, Rebel, and Supercheap, as well as solid industry positions in oligopolies and a solid store network.
  • With over 8 million members, this is an appealing loyalty programme.
  • Making the switch to an omni-channel business. Previously, the business was modelled on like-to-like store numbers; however, management now thinks of business metrics in terms of club members and has been capable of growing active club membership much faster than store numbers (store numbers in the last 5 years have grown +2 percent CAGR vs active club members at +10 percent CAGR), supplying an opportunity to expand customer base and thus (most of the customers are omni channel). Management continues to push for increased online sales (Covid-19 added to this tailwind), with online sales currently accounting for 13-15 percent of total sales and expected to rise to 20-25 percent over the next five years.

Key Risk

  • Increasing competitive pressures.
  • Any supply chain issues, particularly as a result of the impact of Covid-19 on logistics, that have an impact on earnings.
  • Increasing cost pressures are eroding margins (e.g. more brand or marketing investment required due to competitive pressures).
  • A disappointing income update or failure to achieve the market’s expected growth rates could cause the stock price to re-rate significantly lower.

SUL’s Strong Balance Sheet

  • Net cash position of $242.3 million, resulting from a July 2020 equity raise and strong trading throughout the period.
  • Fixed charge cover is 3.1x (based on commonplace EBITDAL) and is anticipated to stabilise in the low to mid 2x range.
  • SUL has $600 million in undrawn committed debt facilities.
  • “While Covid-19-related trading restrictions and lockdowns continue, the Group intends to preserve a very commercially produced position,” said management. 
  • Once trading conditions have normalised, the Group intends to aim for a long-term net debt/EBITDA position (pre AASB 16) of 0 to 0.5x.”

Company Profile 

Super Retail Group (SUL) is one of Australasia’s Top 10 retailers. SUL comprises four core segments. BCF: Australia’s largest outdoor retailer focused on selling Boating, Camping and Fishing products. Macpac: retailer of apparel and equipment with their own designs focused on outdoor adventurers.  Rebel: Retailer of branded sporting and leisure goods and equipment for casual and serious fitness enthusiast. Supercheap Auto: specialty retail business which specialises in automotive parts and accessories.

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

AMN Healthcare Fair Value Estimate to be raised to $71

investment stockbroker risk analysis using multiple devices. Financial analysis using phone app and laptop. Market trading profit.

though recent performance represents a new normal. The company’s fair value estimate has been raised on narrow-moat AMN to $71 per share, up from $55 previously. Labor shortages and resumed healthcare utilization kept revenue up this quarter. Management’s third-quarter guidance provides some clarity for 2021 results, suggesting a sharper decline in the third quarter, which will stabilize in the fourth quarter.

Nursing and Allied revenue fell only 5% sequentially this quarter due to lower nursing volume and bill rates, offset by higher allied revenue. This decline was less than anticipated due not only to lingering COVID-19-related activity but also a thin labor market. A resurgence in patient volume combined with nurse burnout and resignations may limit further declines after third quarter, too. 

Physician and leadership solutions was down 1% sequentially, as COVID-19-related demand mostly ceased in the first quarter, while demand for physician and leadership search remains strong due to vacancies. Technology and workforce solutions grew by 6% sequentially, and the SaaS business should continue its rapid growth, though at a reduced pace as the firm exhausts its lower-hanging partnership opportunities. Gross and operating margin percentages remained stable from the first quarter. 

Company’s Future Outlook

It is expected margins to steadily improve over the next few years, as the technology and workforce solutions segment will be a major driver of margin improvement, eventually overtaking physician and leadership solutions as the second-largest segment. AMN’s recent surge is consistent with the cyclical nature of this business, and is not believed this year represents a suitable point from which to anchor forecasts. Prior history shows that the firm does extraordinarily well during years of growth when need is high but it quickly reverts to baseline industry growth in the years thereafter.

Company Profile

AMN Healthcare Services Inc (NYSE: AMN) is the largest healthcare staffing company in the United States. In 2019, it placed almost 10,000 nurses and allied healthcare full-time workers with provider clients nationwide. About two thirds of its business is generated from its temporary nursing division; the other third is generated from its physician placement and technology-backed workplace solutions divisions.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Philosophy Shares Small Cap Technical Picks

Pact Group’s stock price has risen as a result of a 100% dividend increase.

Investment thesis

  • Strong market share in Australia, with a strong influence in Asia. As a result, it offers appealing exposure to the growth of both developed and emerging markets.
  • The corporation’s newly appointed CEO brings a fresh perspective on company strategy, which can restructure the company for strong volume growth.
  • Based on our projections, the valuation is reasonable.
  • Going forwards, management appears to be less centred on acquired growth, implying that the Company is less likely to make a value-destroying acquisition.
  • The reintroduction of the dividend is a positive sign that management is optimistic about future earnings growth.
  • In an environmentally friendly market, focusing on sustainable packaging.

Key Risks

The following are the key challenges to the investment thesis:

  • Increased competitive pressures, resulting in further margin erosion.
  • Cost pressures on inputs that the corporation would be unable to pass on to users.
  • A worsening in Australia’s and Asia’s economic conditions.
  • The risk of emerging markets.
  • Poor acquisitions or failure to meet synergy targets as PGH shifts away from packaging for food, dairy, and beverage clients and towards more high-growth sectors such as healthcare.
  • Negative currency movements (purchased raw materials in U.S. dollars)

Highlights of key FY21 results

  • Revenue fell -3 percent to $1,762 million, while underlying EBITDA increased by 4% to $315 million, underlying EBIT increased by 10% to $183 million (EBIT margin increased by 120 basis points to 10.4 percent), and underlying NPAT increased by 28% to $94 million. The positive motivational drivers of group EBIT growth over the year were: margin improvement (+$10m) as a result of disciplined raw material input cost management; volume growth in Packaging & Sustainability (+$9m); and volume increase in Materials Handling & Pooling (+$15m).
  • As a result of strong operating performance and working capital management, cash flow performance improved, with free cashflow increasing by +44 percent to $104 million. 
  • Balance sheet gearing decreased slightly year on year, working to improve to 2.4x (within the targeted range of 3.0x) from 2.6x. The company has $317 million in liquid assets (undrawn debt capacity). 
  • Strong capital returns, with a +120bps increase in ROIC to 11.8 percent. The Board declared a final dividend of 6cps (65 percent franked), helping to bring the year’s total dividends to 11cps (vs 3cps in the pcp).

Company Description  

Pact Group Holdings Ltd (PGH) was established by Raphael Geminder in 2002 (Mr. Geminder remains a major shareholder with ~44% and is the brother in law of Anthony Pratt, Chairman of competitor Visy). Pact has operations throughout Australia, New Zealand and Asia and conceives, designs and manufactures packaging (plastic resin and steel) for many productsin the food (especially dairy and beverage), chemical, agricultural, industrial and other sectors. 

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

Sabre Files for Potential Equity Offerings; Shares Cheap

20025825 - closeup image of businessman drawing 3d graphics

sending shares down 8%. In our view, Sabre has enough liquidity in a zero-demand environment for around a year, and probably at least two years at second-quarter 2021 demand levels. This stance is buoyed by Sabre last communicating a monthly cash burn figure of $80 million in a zero-demand environment during its earnings call on 6th Nov 2020. Since then, management said on its Feb. 16, 2021, earnings call that it expected cash burn to improve throughout 2021. On the Aug. 3, 2021, call management said cash burn improved sequentially and that Sabre had $1.1 billion in cash on the balance sheet, with no debt maturing until 2024 and no significant uses for cash in the near term. 

Sabre expects to reach free cash flow break-even levels when its air volumes reach 56%-67% of 2019 levels. Sabre’s total air bookings recovered to 51% of 2019 levels in June, up from 38% in May and 24% in its first quarter. U.S. hotel industry revenue per available room has not weakened through mid-August, and even during 2020 case surges U.S. travel demand only paused for a few weeks before continuing an improving trend, illuminating the desire to travel. Still, after holding at around 80% of 2019 levels through mid-August, U.S. air volumes have averaged around 74% for days 16-19 of the month.

And importantly for Sabre, it is a later cycle recovery play tied to corporate travel improving, which is being delayed by pushouts of return to office. We are monitoring any potential impact to demand from the delta variant of the coronavirus. We currently estimate that Sabre’s second-half 2021 air bookings will reach 54% of 2019 levels, a small improvement from June levels. While share price action may remain volatile, we still see investors greatly discounting Sabre’s narrow moat, with shares trading well below our $16.20 fair value estimate.

Company Profile 

Sabre holds the number-two share of global distribution system air bookings (40.9% as of the end of 2020 versus 38.8% in 2019). The travel solutions segment represented 88% of total 2020 revenue, which was split evenly between distribution and airline IT solutions revenue. The company also has a growing hotel IT solutions division (12% of revenue). Transaction fees, which are tied to volume and not price, account for the bulk of revenue and profits.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Shares Small Cap

Inghams delivered a strong result in spite of national lockdowns in Australia and NZ

Investment Thesis 

  • The pricing condition is improving.
  • The largest integrated poultry producer in Australia and New Zealand.
  • Additional asset sales are planned.
  • Project Accelerate has proven to be effective in increasing labor productivity and automation, resulting in increased earnings despite lower revenue.
  • Procurement measures are being executed, and the results are meeting expectations.
  • Investing in Australia and New Zealand plants to boost capacity and capabilities across the board.
  • With a healthy balance sheet, capital management measures are high on the agenda.

Key Risks

  • Re-negotiation of important contracts with significant clients on less favourable terms.
  • Increased feed and electricity costs, which could be passed on to customers through market price hikes, lowering competitiveness.
  • Uncertainty arises from the lack of information on the appointment of a new CEO.
  • In QSRs (Quick Service Restaurants) and supermarkets, there is a risk of customer concentration.
  • Exotic disease outbreaks are a risk, limiting ING’s ability to produce poultry goods.
  • From the parent stock provider, there has been a significant decline in volume and quality.
  • Material disruptions in ING’s intricate and interconnected supply chain.

Key FY21 group results 

Despite the impact of Covid-19, ING delivered solid FY21 results that were in line with management’s recent guidance (EBITDA & NPAT) issued on May-21. In comparison to the previous year, group revenue increased by +4.4 percent (with Core Poultry volumes increasing by +4.2 percent, with volume growth in NZ exceedingly strong at +6.3 percent), underlying EBITDA increased by +9.6 percent, and underlying NPAT increased by +57.4 percent. Coverage expansion in wholesale and recovery in the QSR and food service channels drove top-line growth. Total dividends increased +17.9 percent year on year to 16.5cps, representing a payout ratio of 71 percent after earnings growth (in line with policy targets of 60 – 80 percent of underlying NPAT post AASB 16 adjustments). The balance sheet is in excellent shape, with net debt falling by -23.7 percent to $240.2 million in the last year. Group leverage fell from 1.8x to 1.2x, well within management’s 1.0–2.0x target range.

Company Description  

Inghams Group Ltd (ING) is Australia and New Zealand’s largest integrated poultry producer. The Company produces and sells chicken, turkey and stock feed that are used by the poultry, pig, dairy and equine industries. Over one quarantine facility, over ten feed mills, over 74 breeder farms, over 11 hatcheries, over 225 predominantly contracted broiler farms, over seven primary processing plants, over seven further processing plants, over one protein conversion plant, and over nine distribution centres are among the Company’s operations in Australia and New Zealand. Ingham’s and Waitoa are two of the company’s brands.

Source: (BanayanTree)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

Maintaining BioNTech FVEs after Comirnaty Approval

received full approval from the U.S. Food and Drug Administration on Aug. 23 for individuals age 16 and older. Pfizer and BioNTech fair value estimates are maintained. The mRNA technology that formed the basis of the vaccine provides support to Pfizer’s established wide moat and also contributes to BioNTech’s positive moat trend.

Government contracts for the initial two-dose series and established contracts are more than sufficient to cover any increased demand. The demand for these purchased vaccines could increase with full approval, which could help to end the most recent surge driven by the delta variant. This could encourage some individuals who were uncertain about the long-term safety of the vaccine to get vaccinated. 

In the U.S., roughly 60% of the vaccine-eligible population has been fully vaccinated. President Joe Biden’s target for a return to near normal by July 4 was thwarted by a combination of vaccine hesitancy, waning efficacy of vaccines, and the rise of the more contagious delta variant. Herd immunity could still be achievable, but the delta variant raises the bar; it therefore could depend on new mandates or increased willingness to vaccinate following Pfizer’s Aug. 23 full approval, uptake of third-dose booster shots, and the potential rise of vaccine-resistant variants down the line. 

Company’s Future Outlook

It continues to see sales reaching $35 billion in 2021 and $39 billion in 2022, followed by roughly $2 billion in annual sales beyond 2022 as it is expected post pandemic annual COVID vaccines for only the most vulnerable (infants and seniors). It is expected this approval to give more leverage to public and private organizations wishing to mandate vaccination, including universities and hospitals.

Full approval also makes it easier for doctors to prescribe off-label use of the vaccine, which could provide more flexibility with the timing of booster shots. Most physicians are waiting for a nod from the Centers for Disease Control’s Advisory Committee on Immunization Practices, which could come next week, before recommending booster shots beyond immunocompromised individuals.

Company Profile

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Dividend Stocks

ASX performed a mixed FY21 as a result of retail trading

Investment Thesis

  • M&A that adds value or product/service innovation
  • Monopoly position in a number of segments, with an EBIT margin of 70% and ROTE of 30%.
  • A quality management team has been established to assist any new CEO. The team has a detailed awareness of future operational and IT requirements, as well as strong ties to legislators and regulators.
  • With net cash and an AA credit rating, the balance sheet is strong.
  • The ASX stands to profit from rising superannuation and population trends.
  • The ASX could profit from global connectivity’s fundamental expansion.

Key Risks

  • Capex execution runs the risk of falling short of expectations in terms of ROIC.
  • Volume growth is expected to be slow, while profitability are expected to be flat.
  • Competitors’ or a new start-technological up’s and product innovation could jeopardise ASX’s market hegemony.
  • Regulation poses a threat.

FY21 results summary

Operating revenue increased +1.4 percent year on year to $951.5 million, driven by strong growth in Listings& Issuer Services (supported by new listings and increased issuer activity), Equity Post-Trade Services (reflecting higher settlement activity), and Trading Services (underpinned by increased demand for information services), partially offset by declines in Derivatives and OTC Markets as current policy settings reverted. Total expenses increased by +8.4 percent years on year to $310.3 million, in line with management’s guidance of +8-9 percent growth, due to additional costs to support licence to operate and growth initiatives, as well as variable costs associated with issuer activity. EBIT fell -1.7 percent years on year, with margin falling -210 basis points to 67.4 percent. Statutory profit was -3.6 percent lower than pcp. Net interest income fell 44.3 percent year on year to $46.7 million as a result of the RBA’s current policy settings, which resulted in lower interest earnings on ASX’s own capital and a lower investment spread on ASX collateral. Capital expenditure (capex) was $109.8 million, up 36.5 percent year on year, reflecting the expanded CHESS replacement project and ASX’s ongoing commitment to strengthen foundations for a future exchange.

Company Description  

ASX Ltd (ASX) operates Australia’s main stock exchange and equity derivatives market. ASX has four core segments:  (1) Listings and Issuer Services (covers capital raisings, investment products, and a range of services ASX provide to listed companies); (2) Derivatives and OTC Markets (covers OTC Clearing, equity options and Austraclear including the ASX collateral management service); (3) Trading Services (encompasses cash equities trading, information services and technical services); and (4) Equity Post-Trade Services (encompasses the clearing and settlement of the entire Australian cash market).

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Dividend Stocks

P&G Cleans Up in Fiscal 2021, but Inflationary and Competive Headwinds Could Stall Its Trajectory

                   

 However, this performance is not solely a by-product of the pandemic, which has seen consumers place an outsize emphasis on cleaning and disinfecting. Rather, we attribute these marks to the strategic course P&G embarked on more than seven years ago (rightsizing its category and geographic reach by shedding more than 100 brands to ensure resources were being effectively allocated to the highest-return opportunities, while maintaining a stringent focus on costs). As a part of this playbook, P&G also adopted a more holistic approach to brand investing across its business .

But even as its top line appears healthy, P&G is facing unrelenting commodity cost inflation that management has qualitatively pegged as some of the most significant in some time. However, we think the degree of inflation combined with P&G’s innovation mandate (rooted in consumer-valued new fare) should make such increases more palatable. Further,  P&G is now involved in leaning into brand spending to illustrate the value its products offer consumers as opposed to turning off the spigot to preserve profits in this uncertain climate. This aligns with our forecast for P&G to direct around 3% and 10%-11% of sales long term to research and development and marketing, respectively, relative to the 2.7% and 10.5% expended on average the past five years.

Financial Strength

P&G maintains solid financial health. The firm continues to throw off a significant amount of cash, with free cash flow amounting to around $15 billion in fiscal 2021 .We expect P&G will remain committed to returning excess cash to shareholders and will increase its dividend, to an average payout ratio north of 60%. For the year 2020 the firms revenue stood at 70.950 USD million while its EBIT was 16,143 USD million. On the other hand the firms EV/EBIDTA was 18.2 while its P/E ratio was 23.4 for the year 2020.

 We believe P&G is also open to bolting on select brands and businesses to its mix over time. The firms acquired Germany-based narrow-moat Merck’s consumer healthcare brands for $4 billion in April 2018. In our view, this deal stood to replace the scale and technological know-how lost following the dissolution of its joint venture partnership with no-moat Teva at the end of fiscal 2018. As such, we don’t think it signals a reversal in the firm’s strategy to operate with a leaner brand mix. Rather, at just 1%-2% of sales, we believe this addition aligned with management’s rhetoric that it intends to selectively bolster its reach in attractive categories (consumer health growing midsingle digits) and geographies. Beyond this deal, P&G has failed to assert itself as a consolidator in the global household and personal-care arena.

Bulls Say

  • To the extent that retailers and consumers continue to find favour with leading branded operators, P&G’s sales trajectory may outpace our expectations.
  • Additional opportunities to narrow its product mix could enable P&G to more effectively direct its brand spending to the highest-return areas.
  • As P&G reaches the end of its second $10 billion cost reduction effort, further savings (probably related to reducing overhead and bolstering the yield on its manufacturing footprint and marketing investments) could manifest if efficiency is as engrained in its culture as management suggests.

Company Profile

Since its founding in 1837, Procter & Gamble has become one of the world’s largest consumer product manufacturers, generating more than $75 billion in annual sales. It operates with a line up of leading brands, including 21 that generate more than $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. P&G sold its last remaining food brand, Pringles, to Kellogg in calendar 2012. Sales outside its home turf represent around 55% of the firm’s consolidated total, with around one third coming from emerging markets.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Funds Funds

A prudent and strong investment strategy that produced absolute returns

Philosophy of the Fund

The Fund’s investment philosophy is based on identifying long-term fundamental value picks that are both listed and unlisted. RARE believes that significant opportunities emerge during economic cycles as markets misprice infrastructure assets in the short term. In the RARE Emerging Markets Strategy, an accumulation index comprised of the FTSE EM Gov Bond Index USD plus 5.0 percent per year is used as a benchmark.

Investment Procedure

The investment team conducts fundamental analysis and valuation in order to identify ‘pure infrastructure’ assets with monopolistic characteristics, long contractual duration, and relatively stable cash flows. In particular, the investments must meet three key requirements:

  • The asset must be a hard-physical asset; 
  • The asset must provide a valuable service to society; and 
  • The asset should have strong foundations in place to ensure equity holders are adequately rewarded.

With these characteristics in mind, RARE uses the ‘RARE EM 150’ as the proprietary investment universe for their Emerging Market Strategy. Included in this list are companies in the MSCI Emerging Markets or Frontier Emerging Markets Index, as well as companies that are listed in other markets but produce a majority of their operating earnings from activities related to emerging markets. Of the 150 securities, 40% of these companies are considered Core and consistently covered, while the remaining 60% are watch listed and updated at least once a year. On a quarterly basis, the composition of the ‘RARE EM 150’ is reviewed by the Investment Leadership Team.

Sector exposure limits are also placed, with a clear preference towards regulated utilities and transport. The Fund notes this is due to their relatively stable performance, and typically lower risk nature in comparison to user-pay assets.

Source: RARE Infrastructure

Fund Positioning 

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.